Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythropoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, followed up for a mean of 9-1 months (range 8-11), haemoglobin concentrations increased from 62 (SD 8) to 105 (9) g/l. No antierythropoietin antibodies were detected during the study. The correction of anaemia was associated with a tendency to hyperkalaemia and a mild increase of unconjugated bilirubinaemia. In eight previously hypertensive patients antihypertensive treatment had to be reinforced, but in normotensive patients blood pressure did not change. Thrombosis of arteriovenous fistulas occurred in two patients and a cerebral ischaemic lesion in one.
Introduction
Several factors may contribute to the pathogenesis of uraemic anaemia but there is general agreement that inadequate secretion of erythropoietin is the main cause.' Recently the gene coding for human erythropoietin has been isolated, characterised,' and cloned in cultured mammalian cells.3 Two clinical studies have shown the efficacy of recombinant erythropoietin in correcting uraemic anaemia,45 but mean follow up was comparatively short. We report the results of replacement treatment with human recombinant erythropoietin given for 8-11 months in a group of 14 patients having regular haemodialysis.
Patients and methods
Fourteen patients receiving haemodialysis who had a stable packed cell volume of less than 022 and had not been transfused in thepast six months entered the study (table I). All gave informed consent. Dialysis was performed with a 1 m2 hollow fibre'dialyser three times a' week for four hours. No causes other than' uraemia accounted for the anemia. On enrolment no patient was iron deficient, as defined by serum iron and ferritin concentrations and percentage of transferrin consumption. Eight patients were taking antihypertensive agents, which maintain-edthieir "i'ean systolic and diastolic pressures within the normal range. Six"patieats were normotensive without treatment.
Human recombinant erythropoietin (AMGen, Thoisiid Oaks, California) was supplied by Cilag SpA(Milan) as a sterile buffered solution in phials containing 0-25% human albumin with h specific activity of 160 000 U human recombinant erythropoietin protein per mg. Initially the study aimed at attaining full correction of the anaemia, defined as a haemoglobin concentration of at least 120 g/l. Later, to reduce the potential hazards of rapid and full correction of the anaemia we decided to lower the target maintenance haemoglobin concentration to between 100 and 120 g/l.
Recombinant erythropoietin was given as an intravenous bolus at the end of dialysis three times a week. The starting dose was 24 U/kg body weight. Doses were doubled every two weeks until a mean increase in the haemoglobin concentration of at least 20 g/l above the mean pretreatment value was achieved in three consecutive determinations. Thereafter, doses were further increased in steps of24 U/kg every two weeks until haemoglobin concentrations were between 100 and 120 g/l. This dose was then given twice a week for two weeks. If haemoglobin concentrations tended to increase further erythropoietin was reduced to once a week for two weeks, the dose then being halved and given once a week for two weeks, and so on, until haemoglobin concentrations were maintained between 100 and 120 g/l.
Blood pressure, pulse rate, respiration rate, and body temperature were measured before and at the end of each dialysis and 60 minutes after each erythropoietin injection. Mean arterial pressure was calculated as dia.stolic pressure plus one third of the difference between systolic and diastolic pressures. Plasma urea, electrolyte, creatinine, protein, albumin, iron, and bilirubin concentrations and transaminase activities were checked weekly. Ferritin concentration, prothrombin time, and partial thromboplastin time were assessed every two weeks. Standard laboratory methods were used. Samples for haemoglobin concentrations and red cell and reticulocyte counts were collected before each dialysis and tested with a Coulter counter. Reticulocytes were counted by standard methods and corrected for red cell counts. Serum erythropoietin concentrations and formation of antierythropoietin antibody were monitored monthly in all patients by radioimmunoassay'6 at Bioscientia Laboratories (Mainz, West Germany). Parathyroid hormone values were determined with a radioimmunoassay kit (Diagnostic Products, Los Angeles). The desferrioxamine test was performed in 13 Linear regression analysis showed a significant relation between the serum erythropoietin concentration and the haemoglobin concentration in eight of the 14 patients (p=0-0012 to p=00374). In one other patient the relation just failed to reach significance (p=00650) and in the remaining five it was not significant (fig 2) . Antierythropoietin antibodies were not detected in any patient.
All patients reported great improvement in wellbeing. Asthenia, fatigue, were determined in triplicate by atomic absorption spectrometry with a graphite furnace8 by CISE Laboratories (Milan). Statistical analysis-The relations between serum erythropoietin concentration and all the relevant variables and between unconjugated bilirubin and haemoglobin concentrations were investigated by simple linear regression analysis, fitted by the least squares method, applied to each patient's data. The relation between plasma aluminium concentrations and doses of erythropoietin was studied by multiple stepwise regression analysis in order to test the linear and quadratic terms of the regression equation.9 Log transformation of serum erythropoietin and aluminium values did not improve the statistical results. The behaviour of the variables recorded on several occasions was tested by analysis of variance for repeated measurements; the significance level ofthe F statistic pertinent to the within patients factor was corrected by the Greenhouse-Geisser procedure.'0 Mean arterial pressure was analysed according to a mixed factorial analysis of variance model with group, measurements (fixed factors at two and four levels respectively), and patients (random factor nested into group). The orthogonal polynomial procedure was used to test the presence of linear and quadratic trends."I All analyses were carried out on a Univac 1100/90 mainframe computer using the SPSS X statistical package for the social sciences" and BMDP statistical software.'3
Results
In one patient (case 10) whose haemoglobin concentration increased by only 19 g/l after six weeks of 384 U recombinant erythropoietin per kg thrice (fig 3) . In three patients unpredictable hypertensive spikes occasionally occurred. Predialysis potassium concentrations tended to increase with the increment of haemoglobin, so that cationic exchange resins had to be given to 11 patients, who had a mean predialysis potassium concentration higher than 5-8 mmol/l. Mean pretreatment total bilirubin concentration (9 4 (SD 3 4) pumol/l) increased, though not significantly, at correction of anaemia to 14-0 (8-55) [umol/l. This increment in bilirubin was mainly due to an increase in the unconjugated fraction-5-3 (2-73) tumol/l before treatment; [umol/l at 25% of total desired haemoglobin increment; 9-74 (6-49) Pmol/l at 50% of haemoglobin increment; 10-9 (5-1) jtmol/l at full correction of anaemia (F3, 36=8-28; p=0-0008). Owing to a significant reduction of plasma iron (F1, 12=21-09; p=0-0006) during erythropoietin treatment iron supplementation was required by 13 patients (table III) .
Three patients complained of bone pain, fever, sweating, shivers, and abdominal cramps, which they described as a "flu-like syndrome." The symptoms appeared 90-120 minutes after any intravenous bolus of erythropoietin and disappeared spontaneously within 10-12 hours. Five patients showed conjunctival inflammation very similar to uraemic "red eye," which occurs with ocular ectopic calcification. This sign, however, was completely asymptomatic and had no relation to plasma calcium or phosphate concentrations. One patient (case 2) had a thrombosis of his arteriovenous fistula, which had been functioning for 10 years, when his packed cell volume increased from 0-18 to 0-40. Another patient (case 10) had episodes of headache, and tachycardia disappeared and many patients returned to work or began new physical activities. A substantial improvement in appetite was reported, and in one patient ideal body weight increased by 2 kg. Angina pectoris, which had been reported occasionally by two patients before the study, no longer occurred after correction of the anaemia.
Recombinant erythropoietin was stopped temporarily in four patients-in two (cases 2 and 3) because of a haemoglobin concentration greater than 140 g/l, in one (case 4) because of reversible focal cerebral ischaemia when the haemoglobin concentration was 122 g/l, and in one (case 9) because of hypertension refractory to treatment. In these patients haemoglobin concentrations (mean 126 (SD 17) g/l) remained stable for two weeks after stopping erythropoietin (120 (12) g/l), then slowly decreased over two weeks to 107 (9) g/l, and fell to 97 (9) g/l six weeks later. The 13 responders required a mean heparin dose of 1071 (SD 335) U/hour in the pretreatment period and a mean dose of 1558 (486) U/hour at full correction of the anaemia (F1, 12=24-01; p=0-0004).
Plasma urea, creatinine, protein, sodium, calcium, and phosphate concentrations did not change significantly during follow up.
SIDE EFFECTS
In normotensive patients the mean arterial pressure did not change, whereas antihypertensive treatment had to be reinforced in the hypertensive group. In some patients the dosage of antihypertensive drugs was doubled, 60 (8) 82 (7) 102 (8) 122 (4) One patient (case 4) developed neurological symptoms. Before the study this patient had been taking 120 mg propranolol and 75 mg hydralazine daily for hypertension. The increase in haemoglobin concentration from 65 to 122 g/l was accompanied by an increase in blood pressure (mean arterial pressure rose from 102 to 113 mm Hg), which was treated with an additional 60 mg nifedipine daily. Mean arterial pressure remained around 108 mm Hg. Reductions in transferrin consumption, serum ferritin concentrations, and especially plasma iron concentrations were recorded during erythropoietin treatment, probably as a consequence of the rapid increase in the synthesis ofhaemoglobin. Iron supplementation is therefore needed during treatment with erythropoietin to prevent iron and ferritin depletion, which might alter the response to erythropoietin.
As expected, the correction of anaemia was accompanied by a substantial improvement in patients' rehabilitation and quality of life, which was maintained over the period of the study. Nevertheless, side effects also occurred. As in the series of Eschbach et al,' most of our patients had a predialysis increase in serum potassium concentration, which almost universally required the regular use of cationic exchange resins during the whole period of follow up.
Hyperkalaemia may have been due to improved appetite with increased potassium in the diet or to increased release of potassium into the plasma from a greater number ofred cells haemolysed daily, as suggested indirectly by the increased concentrations of unconjugated bilirubin in the plasma found in all patients. Whatever the cause the risks of possibly dangerous hyperkalaemia during treatment with erythropoietin should be kept in mind. Though normotensive patients did not show any variation in blood pressure during erythropoietin treatment, in the hypertensive group the correction of anaemia required more vigorous antihypertensive measures. The rise in blood pressure during erythropoietin treatment may be attributable to the increased blood viscosity and total red cell mass, inducing au increase in peripheral resistance. 14 It has also been suggested that anaemia may induce a hypoxic peripheral vasodilatation. If so the correction of anaemia might be accompanied by increased arteriolar resistance, which would worsen hypertension.'5 Despite reinforcement of antihypertensive treatment mean arterial pressure tended to rise in our hypertensive patients with increasing haemoglobin concentrations. Only after erythropoietin dosage was adjusted to keep haemoglobin concentrations around 105 g/l did the mean arterial pressure fall in this group. A tendency to vascular thrombosis was also seen in some patients. This may be due either to increased blood viscosity or to the fact that correction of anaemia may shorten the prolonged bleeding time in uraemic patients. '6 Severe anaemia is one of the most distressing complications of uraemia. It is responsible for asthenia, dyspnoea, tachycardia, headache, reduced appetite, and dizziness and in some cases may precipitate cardiac failure. Nevertheless, teleologically anaemia may serve as a protective factor against cardiovascular complications as it allows better control of. hypertension and reduces platelet adhesiveness. In epidemiological studies patients with mild anaemia had less cardiovascular disease, while mortality was higher in subjects with high packed cell volumes. '7 We suggest that, particularly in patients with arterial hypertension, erythropoietin should initially be given in small doses with small increments to avoid too rapid correction of the anaemia. Moreover, haemoglobin concentrations should be kept around 100 g/l. This "partial correction," while sufficient to reverse most of the symptoms of anaemia, should avoid the risk of increased blood pressure and thrombosis. In patients with refractory hypertension and repeated episodes of thrombosis even lower concentrations of haemoglobin might be considered in order to prevent cardiovascular complications. With these precautions it is unlikely that erythropoietin will trigger important side effects.
